Acumen Pharmaceuticals (ABOS) Receivables (2020 - 2021)

Acumen Pharmaceuticals (ABOS) reported Receivables of $109000.0 for Q3 2021, little changed sequentially from $109000.0 in Q2 2021.

Acumen Pharmaceuticals (ABOS) Receivables (2020 - 2021) Analysis & Trends

Acumen Pharmaceuticals (ABOS) has 2 years of Receivables data on file, last reported at $109000.0 in Q3 2021.

For the quarter ending Q3 2021, Receivables changed N/A year-over-year to $109000.0; the trailing twelve-month figure through Sep 2021 stood at $109000.0 (changed N/A YoY), and the FY2020 full-year result was $109000.0, changed N/A from the prior year.
Receivables steadied at $109000.0 in Q3 2021, from $109000.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $109000.0 in Q4 2020 to a low of $109000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	4.97 Mn
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	938.02 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	-
10	Acumen Pharmaceuticals	140.98 Mn	140.98 Mn	-	-

Download Data